{
    "clinical_study": {
        "@rank": "137901", 
        "arm_group": [
            {
                "arm_group_label": "Normal Hepatic Function", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with normal hepatic function"
            }, 
            {
                "arm_group_label": "Mild Hepatic Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with mild hepatic impairment"
            }, 
            {
                "arm_group_label": "Moderate Hepatic Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with moderate hepatic impairment"
            }, 
            {
                "arm_group_label": "Severe Hepatic Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with severe hepatic impairment"
            }
        ], 
        "brief_summary": {
            "textblock": "Pharmacokinetics and safety of 750 mg of LDK378 given once orally in subjects with impaired\n      hepatic function and healthy subjects with normal hepatic function."
        }, 
        "brief_title": "Effect of Hepatic Impairment on LDK378 Pharmacokinetics", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Normal Hepatic Function", 
            "Impaired Hepatic Function"
        ], 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (all groups):\n\n          -  Male Subjects between 18-70 years of age\n\n          -  Female subjects between 18-70 years of age who are postmenopausal or sterile\n\n          -  Body Mass Index (BMI) of 18.0- 35.0 kg/m2, with body weight \u2265 50 kg.\n\n        Inclusion (group mild, moderate and severe hepatic impairment):\n\n        - Subjects with confirmed cirrhosis\n\n        Exclusion Criteria (all groups):\n\n          -  impaired cardiac function\n\n          -  concurrent severe and/or uncontrolled medical conditions\n\n        Exclusion Criteria (moderate, mild and severe groups):\n\n        - Clinical evidence of severe ascites"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950481", 
            "org_study_id": "CLDK378A2110"
        }, 
        "intervention": {
            "arm_group_label": [
                "Normal Hepatic Function", 
                "Mild Hepatic Impairment", 
                "Moderate Hepatic Impairment", 
                "Severe Hepatic Impairment"
            ], 
            "description": "Oral LDK378 750 mg once", 
            "intervention_name": "LDK378", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "LDK378", 
            "pharmacokinetics", 
            "hepatic impairment"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "contact": {
                    "phone": "303-566-3008"
                }, 
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80228"
                    }, 
                    "name": "DaVita Clinical Research-Denver"
                }, 
                "investigator": {
                    "last_name": "Chris Galloway", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "407-472-0228"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32086"
                    }, 
                    "name": "Orlando Clinical Research Center"
                }, 
                "investigator": {
                    "last_name": "Thomas C. Marbury", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "612-347-6206"
                }, 
                "facility": {
                    "address": {
                        "city": "Miinneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "DaVita Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Jolene Berg", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDK378 in Subjects With Hepatic Impairment Compared to Subjects With Normal Hepatic Function", 
        "other_outcome": [
            {
                "description": "Explore the relationship between PK and hepatic function parameters", 
                "measure": "Relationship between PK and hepatic function parameters", 
                "safety_issue": "Yes", 
                "time_frame": "18 Days"
            }, 
            {
                "description": "4\u03b2-hydroxycholesterol level", 
                "measure": "4\u03b2-hydroxycholesterol level", 
                "safety_issue": "No", 
                "time_frame": "18 Days"
            }
        ], 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate the pharmacokinetics of a single dose of LDK378 in subjects with impaired hepatic function as compared to healthy subjects", 
            "measure": "LDK378 pharmacokinetic parameters (Tmax, Cmax, AUClast, AUCinf, T1/2, CL/F, Vz/F)", 
            "safety_issue": "Yes", 
            "time_frame": "18 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950481"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety will be determined by the frequency of adverse events and the frequency of laboratory toxicities.", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "18 Days"
            }, 
            {
                "description": "Plasma protein binding of LDK378", 
                "measure": "Plasma protein binding of LDK378", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}